Dr. Dipenkumar Modi is an Assistant Professor of Medicine and Oncology at Barbara Ann Karmanos Cancer Institute/Wayne State University in Detroit, Michigan. He is a member of the Malignant Hematology and Bone Marrow Transplant multidisciplinary teams, and Molecular Therapeutics programs. His areas of expertise include management of aggressive and indolent B-cell non-Hodgkin’s lymphoma, T-cell non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, and chronic lymphocytic leukemia, as well as CAR-T cell therapy, and stem cell transplant.

Dr. Modi completed his Internal Medicine residency from Wayne State University in 2015. He then served as a Chief Resident in the Department of Internal Medicine. He completed Hematology/Oncology Fellowship from Karmanos Cancer Institute/Wayne State University in 2019 and served as a Chief fellow in 2018-19. In 2017, he was the recipient of American Society of Hematology (ASH) abstract achievement award for his outstanding research work. He received 2022 Ernest McCulloch & James Till Award for best basic science article by a new investigatory by the Transplantation and Cellular Therapy. He is board certified in Hematology and Oncology by the American Board of Internal Medicine. He is an active member of the American Society of Hematology, American Society of Clinical Oncology, Transplantation and Cellular Therapy, Michigan Society of Hematology/Oncology, and Southwest Oncology Group.

Dr. Modi is also affiliated with the Molecular Therapeutics Program at Karmanos Cancer Institute. His research interests include novel therapeutic agents to improve outcomes of aggressive B-cell non-Hodgkin’s lymphoma. He leads investigator-initiated trials focusing in non-Hodgkin’s lymphoma. He has presented a number of research articles in the national and international conferences and published extensively in several peer reviewed journals.